Project: Effective Treatment for sporadic inclusion body myositis (sIBM)

The objective of the project is to deliver a commercially available treatment for Sporadic Inclusion-body Myositis (sIBM) – a progressively disabling muscle disease with currently no effective treatment. The result is the first available disease-modifying drug on the market. We will do this by monitoring a phase III clinical trial verifying the efficacy of the compound arimoclomol in patients to ensure that the quality of the trial data corresponds with the expectations of authorities.

Acronym	TREAT-sIBM (Reference Number: 10533)
Duration	01/07/2016 - 01/07/2019
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
24405	Orphazyme ApS	Coordinator	Denmark
24406	UCL Institute of Neurology	Partner	United Kingdom